Dexmedetomidine in Off Pump Coronary Artery Bypass Grafting

May 22, 2026 updated by: Abdelrhman Alshawadfy, Suez Canal University

Echocardiographic Evaluation of the Effect of Dexmedetomidine Infusion as an Adjuvant to General Anesthesia in Off-pump Coronary Artery Bypass Grafting

the study will assess the impact of intraoperative dexmedetomidine infusion on myocardial performance by investigating the left ventricular (LV) systolic and diastolic function and right ventricular (RV) fraction area change (which reflect RV systolic function) using two-dimensional trans-esophageal echocardiography (TEE) in patients undergoing elective first-time isolated off-pump coronary artery bypass (OPCAB) grafting. LV Systolic function will be measured by the TEE via the fractional area change, fraction shortening, and ejection fraction.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Off pump coronary revascularization is an old technique performed first in St Petersburg in 1964, Off pump coronary artery surgery has been developed following two different approaches. Minimally invasive direct-access coronary artery bypass (MIDCAB) that consists of anastomosing the left internal mammary artery to the left anterior descending coronary artery through small anterior left thoracotomy, The second approach is multi-vessel grafting without CPB performed through standard median sternotomy. Dexmedetomidine (Dex), a highly selective α2-adrenergic receptor agonist, is widely used for sedation and analgesia in the ICU or as an anesthetic adjuvant.

This study will be a prospective comparative controlled randomized double blinded clinical trial on 36 patients divided into control ,and dexmedetomidine group.

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Ismailia, Egypt
        • Faculty of Medicine, Suez Canal University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients undergoing elective first-time off-pump isolated coronary artery bypass graft (OPCAB) surgery
  • Patients with good ventricular functions.
  • Patients with normal levels of cardiac troponin I and myocardial enzymes
  • Patients of Body Mass Index (BMI) more than 20 and less than 34.

Exclusion Criteria:

  • Severe functional liver or kidney disease.
  • Diagnosed HF (NYHA class >3).
  • Arrhythmia or received treatment with anti-arrhythmic drugs.
  • Severe bradycardia (HR < 45 bpm) and AV block.
  • Pathologic esophageal lesion (esophageal stricture or varix )
  • Pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: dex group
patients medicated with dexmedetomidine.
Drug: Dexmedetomidine
infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery
Placebo Comparator: control group
patients took placebo normal saline.
Drug: normal saline
infusion of normal saline during the off pump coronary artery bypass grafting surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
left ventricular ejection fraction
Time Frame: immediatly after sternal closure
using transesophageal echocardiography, ejection fraction will be assessed by the ratio of stroke volume and end diastolic volume
immediatly after sternal closure
left ventricular fractional shorting
Time Frame: immediatly after sternal closure
using transesophageal echocardiography, fractional area change of the left ventricle will be calculated
immediatly after sternal closure
left ventricular diastolic function
Time Frame: immediatly after sternal closure
using transesophageal echocardiography, diastolic function (filling ratio) will be assessed by the ratio between early transmitral flow (E) and mitral annular tissue velocity (E').
immediatly after sternal closure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
right ventricular systolic function
Time Frame: immediatly after sternal closure
right ventricular systolic function assessed by (fraction area change) as assessed using transesophageal echocardiography.
immediatly after sternal closure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Suez Canal University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2022

Primary Completion (Actual)

February 28, 2023

Study Completion (Actual)

September 30, 2024

Study Registration Dates

First Submitted

October 8, 2022

First Submitted That Met QC Criteria

October 11, 2022

First Posted (Actual)

October 13, 2022

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 22, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Dex in CABG

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe